CYAD-N2T-002 (THINK) (R/R)
A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types (THINK)
Study treatments
- Administration of NKR-2 cells intravenous
Inclusion criteria
- Age 18 years or older
- Patient with Acute Myeloid Leukemia/Myelodysplasia or Multiple Myeloma
- Disease must be measurable according to the corresponding guidelines
- ECOG score of 0-1
- Patient with adequate bone marrow reserve, hepatic and renal functions
Exclusion criteria
- Patient with a tumor metastasis in the central nervous system
- Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis
- Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration
- Patients who are planned to receive concurrent growth factor, systemic steroid or other immunosuppressive therapy or cytotoxic agent
- Patients who have received other cell therapies
- Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration
Participating sites
- Ghent University Hospital
- Institut Jules Bordet
- Cliniques Universitaires UCL Saint Luc